As of 2025-07-20, the Intrinsic Value of Aeglea Bio Therapeutics Inc (AGLE) is -363.49 USD. This AGLE valuation is based on the model Peter Lynch Fair Value. With the current market price of 12.01 USD, the upside of Aeglea Bio Therapeutics Inc is -3,126.59%.
Based on its market price of 12.01 USD and our intrinsic valuation, Aeglea Bio Therapeutics Inc (AGLE) is overvalued by 3,126.59%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -363.49 - -363.49 | -363.49 | -3,126.59% |
| P/E | (1,254.78) - (1,741.86) | (1,553.94) | -13038.7% |
| DDM - Stable | (425.85) - (1,325.25) | (875.55) | -7390.2% |
| DDM - Multi | (107.50) - (270.03) | (154.87) | -1389.5% |
| Market Cap (mil) | 48.64 |
| Beta | 0.13 |
| Outstanding shares (mil) | 4.05 |
| Enterprise Value (mil) | -41.96 |
| Market risk premium | 5.00% |
| Cost of Equity | 12.44% |
| Cost of Debt | 5.00% |
| WACC | 8.06% |